12.70EUR
3.28 BEUR
8.91 BEUR
257.54 M
About VERTEX PHARMACEUTICALS INC.
Sector
CEO
Reshma Kewalramani
Headquarters
Boston
Website
Employees (FY)
5.4 K
Founded
1989
ISIN
US92532F1003
FIGI
BBG000GNZT36
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where VX1 is featured.
Frequently Asked Questions
The current price of VX1 is 367.00 EUR — it has decreased by 0.50% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange VERTEX PHARMACEUTICALS INC. stocks are traded under the ticker VX1.
VERTEX PHARMACEUTICALS INC. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
VX1 stock is 0.50% volatile and has beta coefficient of 0.94. Check out the list of the most volatile stocks — is VERTEX PHARMACEUTICALS INC. there?
One year price forecast for VERTEX PHARMACEUTICALS INC. has a max estimate of 540.65 EUR and a min estimate of 306.10 EUR.
VX1 earnings for the last quarter are 3.86 EUR whereas the estimation was 3.72 EUR which accounts for 3.72% surprise. Estimated earnings for the next quarter are 3.68 EUR. See more details about VERTEX PHARMACEUTICALS INC. earnings.
VERTEX PHARMACEUTICALS INC. revenue for the last quarter amounts to 2.35 B EUR despite the estimated figure of 2.37 B EUR. In the next quarter revenue is expected to reach 2.28 B EUR.
Yes, you can track VERTEX PHARMACEUTICALS INC. financials in yearly and quarterly reports right on TradingView.
VX1 stock has fallen by 1.63% compared to the previous week, the month change is a 2.95% fall, over the last year VERTEX PHARMACEUTICALS INC. has showed a 22.95% increase.
VX1 net income for the last quarter is 877.74 M EUR, while the quarter before that showed 979.39 M EUR of net income which accounts for −10.38% change. Track more VERTEX PHARMACEUTICALS INC. financial stats to get the full picture.
Today VERTEX PHARMACEUTICALS INC. has the market capitalization of 95.50 B, it has decreased by 2.06% over the last week.
No, VX1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VX1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMACEUTICALS INC. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 5.40 K employees. See our rating of the largest employees — is VERTEX PHARMACEUTICALS INC. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMACEUTICALS INC. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMACEUTICALS INC. stock shows the buy signal. See more of VERTEX PHARMACEUTICALS INC. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on VERTEX PHARMACEUTICALS INC. future price: according to them, VX1 price has a max estimate of 540.66 EUR and a min estimate of 306.12 EUR. Read a more detailed VERTEX PHARMACEUTICALS INC. forecast: see what analysts think of VERTEX PHARMACEUTICALS INC. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMACEUTICALS INC. EBITDA is 3.58 B EUR, and current EBITDA margin is 45.32%. See more stats in VERTEX PHARMACEUTICALS INC. financial statements.